Novavax Inc. (NVAX)
Novavax beats quarterly revenue estimates on milestone payment
Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone payment related to U.S. approval of its COVID-19 vaccine in May.
Novavax (NVAX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the most recent trading session, Novavax (NVAX) closed at $6.85, indicating a -2.28% shift from the previous trading day.
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade
Novavax (NVAX) reached $7.64 at the closing of the latest trading day, reflecting a -2.55% change compared to its last close.
Novavax (NVAX) Rises Higher Than Market: Key Facts
In the closing of the recent trading day, Novavax (NVAX) stood at $6.97, denoting a +1.9% move from the preceding trading day.
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade
The latest trading day saw Novavax (NVAX) settling at $6.36, representing a -2.15% change from its previous close.
Novavax (NVAX) Ascends While Market Falls: Some Facts to Note
Novavax (NVAX) concluded the recent trading session at $6.41, signifying a +1.75% move from its prior day's close.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.
Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Novavax, Inc. (NASDAQ:NVAX ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ET Company Participants James Patrick Kelly - Executive VP, CFO & Treasurer John Charles Jacobs - President, CEO & Director Ruxandra Draghia-Akli - EVP and Head of Research & Development John Charles Jacobs Are we ready to go? Are we live?
